Susan R. Goulding

Cork, M, Ireland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Human α-synuclein overexpression upregulates SKOR1 in a rat model of simulated nigrostriatal ageing.

Human α-synuclein overexpression upregulates SKOR1 in a rat model of simulated nigrostriatal ageing.

Journal: Aging cell

Published: January 11, 2024

Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.

Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: January 31, 2023

Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.

Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.

Journal: Brain, behavior, and immunity

Published: November 11, 2021

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.

Journal: Neural regeneration research

Published: June 08, 2021

LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease.

LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease.

Journal: Molecular and cellular neurosciences

Published: March 04, 2021

NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease.

NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease.

Journal: Molecular neurobiology

Published: December 11, 2020

Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and α-Synuclein-Induced Neurodegeneration.

Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and α-Synuclein-Induced Neurodegeneration.

Journal: Molecular neurobiology

Published: December 09, 2020

Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson's disease.

Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson's disease.

Journal: Brain : a journal of neurology

Published: November 30, 2020

STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5.

STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5.

Journal: iScience

Published: April 03, 2020

The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease.

The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease.

Journal: Neural regeneration research

Published: January 31, 2020

Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein.

Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein.

Journal: Parkinsonism & related disorders

Published: November 23, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026